IN THE CLAIMS

Please amend the claims as follows:

- 1. (Withdrawn) An antibody that specifically binds to a Cav3 isoform or its δ25 splicing variants thereof.
- 2. (Withdrawn) The antibody of Claim 1, wherein the Cav3 isoform is a Cav3.2 isoform.
- (Withdrawn) The antibody of Claim 1, wherein the antibody is a humanized antibody. 3.
- 4. (Withdrawn) A pharmaceutical composition comprising an antibody of Claim 1 and a pharmaceutically acceptable carrier.
- 5. (Withdrawn) A method for diagnosing cancer comprising detecting the presence of a Cav3 isoform protein and/or its δ 25B splice variant in a tissue sample from a patient.
- 6. (Withdrawn) A method for treating cancer comprising detecting the presence of a Cav3 isoform protein and/or its 825B splice variant in a patient according to Claim 5 and administering to the patient a therapeutically effective amount of an antibody against the Cav3 isoform and/or its $\delta 25B$.
- 7. (Currently Amended) A method for inducing cytostasis comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor so as to induce cytostasis in said patient.

8. (Original) The method of Claim 7, wherein the T type calcium channel selective inhibitor is a tetrahydronaphthalene derivative of the formula

$$R^{1}$$
 R^{2}
 CH_{2}

wherein R^1 is a halogen, R^2 is a lower-alkoxy-lower-alkyl-carbonyloxy, X is a C_2 - C_8 -alkylene, and A is a benzimidazolyl optionally substituted at the N atom with 1 to 12 C atoms in the form of their free bases, their hydrates, or their pharmaceutically usable salts for the treatment, control, and prevention of cancer.

- 9. (Original) The method of Claim 7, wherein the T type calcium channel selective inhibitor is a mibefradil of the formula (1S,2S)-(2{[3-(2-benzimidazolyl) propyl] methylamino} ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthylmethoxyacetate dihydrochloride.
- 10. (Currently Amended) A method of inhibiting cancer <u>cell</u> eall proliferation comprising administering to a patient in need thereof a therapeutically effective amount of mibefradil <u>so as to induce cytostasis in the patient</u>.

Claims 11-12 (Cancelled).

- 13. (Withdrawn) A method of treating autoimmune diseases comprising administering to a patient in need thereof a threapeutically effective amount of T type calcium channel selective inhibitor.
- 14. (Withdrawn) A method for preventing graft rejections comprising administring to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. \S 1.116 - EXPEDITED PROCEDURE

Serial Number: 10/589,216 Filing Date: January 15, 2008

Title: Inhibiting Cav3 Isoforms and the 25B Splice Variants for the Diagnosis and Treatment of Cancer (Amended)

15. (Withdrawn) A method for preventing apoptosis comprising administering to a patient in need thereof a therapeutically effective amount of T type calcium channel selective inhibitor.

Page 5 Dkt: 1036.115US1